PhiTech, a biotech startup developing genomics and AI-driven solutions, has raised $2.4 million

PhiTech, a biotechnology company integrating genomics and artificial intelligence to address rare diseases, has raised $2.4 million in funding.

The investment round was led by Entertech Venture Capital Fund (GSYF), established through a collaboration between Entertech İstanbul Teknokent and Yapı Kredi Portfolio. The round also saw participation from Eksim Ventures, Founder One, İTK Ventures, TechnoBee, Arya VC, İstcapital, Gelecek Etki GSYF, along with a group of angel investors including Muharrem Usta, Kamil Buğra Rodoper, Banu Başaran, Mert Erdoğmuş, Ahmet Kemal Atasoy, Dr. Adem Akkaya, Zeynep Seval, Selami Düz, Candan Karabağlı, and Osman Alp Arlı.

The company plans to use the funding to scale its multi-layered AI solutions focused on rare diseases and to advance the R&D of its oncology-oriented products.

Founded in 2013 by Dr. Saliha Durmuş, Prof. Tunahan Çakır, and Prof. Fatih Erdoğan Sevilgen, PhiTech has developed its proprietary G&M (Genomics & More) platform, enabling integrated analysis of DNA and RNA data. This approach enhances both diagnostic speed and accuracy, particularly in rare diseases and oncology.

By moving beyond traditional DNA-only genetic testing, PhiTech leverages multi-layered data analysis to deliver clinically actionable insights. Its platform supports hospitals, genetic diagnostic laboratories, and pharmaceutical companies in clinical decision-making, patient management, and drug development—contributing to faster diagnoses and the broader adoption of precision medicine.